Pancreatic Cancer
Conditions
Interventions
GEM group:Gemcitabine 1000mg/m2, intravenous infusion, once a week, after three consecutive weeks stop for a week, for a cycle, a total of 6 cycles
AG group:Albumin paclitaxel 125mg / m2 + gemcitabine 1000mg / m2, intravenous infusion, once a week, stopping for three weeks after a week, for a period of 6 cycles
Sponsors
East China Hospital Affiliated to Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients who voluntarily participate in and sign informed consent; 2. Patients aged >= 18 years and <= 80 years, regardless of gender; 3. Patients who did not receive any chemotherapy 4-12 weeks after operation; 4. Patients with pancreatic ductal adenocarcinoma confirmed by postoperative pathology; 5. Pathological stage: t1-3, n0-1, M0; 6. Patients with R0 or R1 resection; 7. ECoG physical condition score: 0-1.
Exclusion criteria
Exclusion criteria: 1. Patients with metastasis or recurrence were found by CT examination before chemotherapy; 2. Patients with other systemic malignancies; 3. Patients with other systemic diseases that are not suitable for chemotherapy; 4. Patients with any condition that may damage the safety of patients or the integrity of research data, including serious medical risk factors, medical conditions, and laboratory abnormalities.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free Survival;the mutation of ctDNA KRAS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival; | — |
Countries
China
Contacts
Public ContactJiang Chongyi
East China Hospital Affiliated to Fudan University
Outcome results
None listed